Mark Leuchtenberger

Chief Executive Officer

Mark Leuchtenberger has over 20 years of experience as a CEO in the biopharmaceutical industry and has led companies through private financings and initial public offerings, taken products from research to IND and through commercialization, and achieved multiple M&A exits. Prior to joining SpyBiotech in 2022, he served as Executive Chairman for Aleta Biotherapeutics, CEO of Brooklyn ImmunoTherapeutics and Chairman, President and CEO of IRX Therapeutics. Leuchtenberger was President, CEO and a Board member at Chiasma (NASDAQ: CHMA), Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.), Targanta Therapeutics Corporation, and Therion Biologics Corporation. Prior to Therion, he was a senior officer at Biogen Inc., where he led the late-stage development of the company’s flagship product Avonex and its commercialization and market leadership in North America and internationally in 65 countries. He is a past chairman of the Massachusetts Biotechnology Council Board of Directors, co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc., and currently serves as Board Chairman for Neurosense Therapeutics (NASDAQ: NRSN). He received his MBA from the Yale School of Management and his BA from Wake Forest University.